Leonid Timashev
Stock Analyst at RBC Capital
(3.94)
# 755
Out of 5,182 analysts
175
Total ratings
49.68%
Success rate
10.52%
Average return
Main Sectors:
Stocks Rated by Leonid Timashev
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ONC BeOne Medicines AG | Maintains: Outperform | $423 → $425 | $314.69 | +35.05% | 7 | May 7, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $195 → $258 | $226.15 | +14.08% | 5 | May 6, 2026 | |
| CYTK Cytokinetics | Maintains: Outperform | $101 → $119 | $74.47 | +59.80% | 8 | May 6, 2026 | |
| BRCC BRC Inc. | Maintains: Buy | $2.5 | $1.23 | +103.25% | 2 | May 5, 2026 | |
| NUVB Nuvation Bio | Reiterates: Outperform | $20 | $4.77 | +319.29% | 6 | May 5, 2026 | |
| BHVN Biohaven | Maintains: Outperform | $23 → $22 | $9.76 | +125.41% | 16 | May 5, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $242 → $302 | $217.68 | +38.74% | 17 | May 5, 2026 | |
| ADCT ADC Therapeutics | Reiterates: Outperform | $6 | $3.76 | +59.79% | 2 | May 5, 2026 | |
| CRMD CorMedix | Maintains: Outperform | $13 → $14 | $7.85 | +78.31% | 4 | Apr 28, 2026 | |
| CGON CG Oncology | Maintains: Outperform | $73 → $79 | $67.78 | +16.55% | 4 | Apr 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $140 → $162 | $143.55 | +12.85% | 3 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $212 → $216 | $107.35 | +101.21% | 9 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $53 | $28.17 | +88.14% | 6 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $11 → $7 | $4.87 | +43.74% | 3 | Mar 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $14 | $3.57 | +292.16% | 2 | Mar 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 → $62 | $28.51 | +117.47% | 16 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $14 | $14.10 | -0.71% | 11 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $46 → $43 | $45.90 | -6.32% | 4 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $45 | $35.67 | +26.16% | 6 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $9.34 | +135.55% | 6 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $47 | $33.50 | +40.30% | 9 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $5 | $2.23 | +124.22% | 7 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $0.90 | +343.46% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $50 | $35.47 | +40.96% | 15 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $19 | $12.32 | +54.22% | 3 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $13 | $5.68 | +128.87% | 2 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $97.62 | -28.29% | 1 | Jan 23, 2025 |
BeOne Medicines AG
May 7, 2026
Maintains: Outperform
Price Target: $423 → $425
Current: $314.69
Upside: +35.05%
Jazz Pharmaceuticals
May 6, 2026
Maintains: Outperform
Price Target: $195 → $258
Current: $226.15
Upside: +14.08%
Cytokinetics
May 6, 2026
Maintains: Outperform
Price Target: $101 → $119
Current: $74.47
Upside: +59.80%
BRC Inc.
May 5, 2026
Maintains: Buy
Price Target: $2.5
Current: $1.23
Upside: +103.25%
Nuvation Bio
May 5, 2026
Reiterates: Outperform
Price Target: $20
Current: $4.77
Upside: +319.29%
Biohaven
May 5, 2026
Maintains: Outperform
Price Target: $23 → $22
Current: $9.76
Upside: +125.41%
Axsome Therapeutics
May 5, 2026
Maintains: Outperform
Price Target: $242 → $302
Current: $217.68
Upside: +38.74%
ADC Therapeutics
May 5, 2026
Reiterates: Outperform
Price Target: $6
Current: $3.76
Upside: +59.79%
CorMedix
Apr 28, 2026
Maintains: Outperform
Price Target: $13 → $14
Current: $7.85
Upside: +78.31%
CG Oncology
Apr 27, 2026
Maintains: Outperform
Price Target: $73 → $79
Current: $67.78
Upside: +16.55%
Apr 14, 2026
Maintains: Outperform
Price Target: $140 → $162
Current: $143.55
Upside: +12.85%
Apr 14, 2026
Maintains: Outperform
Price Target: $212 → $216
Current: $107.35
Upside: +101.21%
Apr 14, 2026
Maintains: Outperform
Price Target: $49 → $53
Current: $28.17
Upside: +88.14%
Mar 18, 2026
Maintains: Sector Perform
Price Target: $11 → $7
Current: $4.87
Upside: +43.74%
Mar 17, 2026
Maintains: Outperform
Price Target: $18 → $14
Current: $3.57
Upside: +292.16%
Mar 11, 2026
Maintains: Outperform
Price Target: $66 → $62
Current: $28.51
Upside: +117.47%
Mar 10, 2026
Maintains: Outperform
Price Target: $13 → $14
Current: $14.10
Upside: -0.71%
Mar 2, 2026
Maintains: Sector Perform
Price Target: $46 → $43
Current: $45.90
Upside: -6.32%
Feb 26, 2026
Maintains: Outperform
Price Target: $47 → $45
Current: $35.67
Upside: +26.16%
Feb 18, 2026
Maintains: Outperform
Price Target: $21 → $22
Current: $9.34
Upside: +135.55%
Jan 21, 2026
Maintains: Outperform
Price Target: $44 → $47
Current: $33.50
Upside: +40.30%
Dec 19, 2025
Maintains: Outperform
Price Target: $8 → $5
Current: $2.23
Upside: +124.22%
Nov 11, 2025
Maintains: Sector Perform
Price Target: $5 → $4
Current: $0.90
Upside: +343.46%
Nov 7, 2025
Maintains: Outperform
Price Target: $49 → $50
Current: $35.47
Upside: +40.96%
Nov 6, 2025
Maintains: Outperform
Price Target: $18 → $19
Current: $12.32
Upside: +54.22%
Aug 8, 2025
Maintains: Outperform
Price Target: $12 → $13
Current: $5.68
Upside: +128.87%
Jan 23, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $97.62
Upside: -28.29%